Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): April 15, 2020





(Exact name of registrant as specified in Charter)




Washington   001-35521   26-2056298

(State or other jurisdiction of

incorporation or organization)

  (Commission File No.)   (IRS Employee Identification No.)


12870 Interurban Avenue South

Seattle, Washington 98168

(Address of Principal Executive Offices)



(Issuer Telephone number)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below).


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR240.14a-12)


¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).


¨Pre-commencement communications pursuant to Rule 13e-(c) under the Exchange Act (17 CFR 240.13(e)-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   CLIR   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On April 15, 2020, Dr. Lon E. Bell, a member of the Board of Directors (the “Board”) of ClearSign Technologies Corporation (the “Company”) informed the Board that he did not intend to stand for reelection at the Company’s upcoming annual shareholder meeting, which was originally scheduled for May 7, 2020 but has been rescheduled for June 17, 2020 (the “Annual Meeting”). (See Item 8.01 below.) Dr. Bell’s decision is not due to a disagreement between Dr. Bell and the Company on any matter relating to the Company’s operations, policies or practices. Dr. Bell intends to continue to serve as a director through the remainder of his current term.


Also on April 15, 2020, and in accordance with Section 3, paragraph 3.2 of the Company’s bylaws, the Board reduced the number of directors from 5 to 4, effective as of the date of the Annual Meeting.


Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.


To the extent required by this Item 5.03, the information included in paragraph two of Item 5.02 above is incorporated herein in its entirety.


Item 8.01Other Events.


On February 20, 2020, the Company filed a Current Report on Form 8-K disclosing that the Annual Meeting was scheduled for May 7, 2020. However, due to the overwhelming demand for virtual shareholder meetings, the provider of the platform for online meetings has notified the Company that it is unable to provide the Company with the tools necessary to host the meeting on that date. Therefore, the Company has rescheduled the Annual Meeting for June 17, 2020. The record date for the rescheduled Annual Meeting is April 24, 2020.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: April 17, 2020


  By: /s/ Brian G. Fike
    Brian G. Fike
    Chief Financial Officer